SCHEMBL2735283

SCHEMBL2735283

Cc1c(Cl)cccc1NC(=O)c1nc[nH]c1C(=O)Nc1nc2ccccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
HPGD P15428 3/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 4/20 0.48
GAA P10253 1/20 0.48
CYP1A2 P05177 1/20 0.48
LMNA P02545 1/20 0.48
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
PKM P14618 2/20 0.47
OPRK1 P41145 1/20 0.47
KLF5 Q13887 1/20 0.47
KDM4E B2RXH2 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAOB P27338 1/20 0.46
ADORA2A P29274 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735280 0.90 GAA (0.55) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2735268 0.87 GAA (0.65) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2735344 0.87 NPC1 (0.52) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2759975 0.86 SMN1; SMN2 (0.50) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2735384 0.86 SMN1; SMN2 (0.47) SMN1; SMN2HPGDMAPK1KMT2AMEN1
SCHEMBL213456 0.85 NPC1 (0.50) SMN1; SMN2HPGDKMT2AALDH1A1MEN1
SCHEMBL2735338 0.84 KMT2A (0.50) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2735295 0.84 MEN1 (0.50) SMN1; SMN2HPGDKMT2AALDH1A1MEN1
SCHEMBL214896 0.84 NPC1 (0.52) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1
SCHEMBL2735267 0.84 NPC1 (0.52) SMN1; SMN2HPGDMAPK1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 SMN1; SMN2 2516/4885HPGD 3138/4885MAPK1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.